|Bid||135.29 x 700|
|Ask||135.95 x 100|
|Day's Range||135.10 - 136.27|
|52 Week Range||109.32 - 137.08|
|PE Ratio (TTM)||22.74|
|Dividend & Yield||3.36 (2.48%)|
|1y Target Est||N/A|
Which big pharma stock wins in a head-to-head battle between Johnson & Johnson and AbbVie?
South Korea’s Samsung conglomerate, best known for its smartphones and televisions, will make available on Monday in the U.S. its lower-price copy of Johnson & Johnson’s blockbuster rheumatoid-arthritis ...
South Korea's Samsung Bioepis Co Ltd said it started U.S sales of its copy of Johnson & Johnson's rheumatoid arthritis drug Remicade on Monday - a move set to further undermine sales of the U.S. firm's top-selling drug. It is the second cheaper biosimilar version of Remicade to be sold after Pfizer Inc's Inflectra. Remicade had U.S. sales of $4.8 billion last year, but January-June sales fell 8.2 percent from a year earlier to $2.2 billion on its new competition.